Celcuity Inc. (NASDAQ:CELC – Get Free Report) was the target of a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 2,550,000 shares, a growth of 11.4% from the August 31st total of 2,290,000 shares. Based on an average daily volume of 416,400 shares, the short-interest ratio is currently 6.1 days.
Celcuity Price Performance
CELC traded up $0.16 during trading on Friday, hitting $14.40. The company’s stock had a trading volume of 101,975 shares, compared to its average volume of 291,706. The firm has a market capitalization of $505.45 million, a price-to-earnings ratio of -5.18 and a beta of 0.76. Celcuity has a twelve month low of $8.39 and a twelve month high of $22.19. The business’s fifty day simple moving average is $16.27 and its 200 day simple moving average is $16.75. The company has a current ratio of 14.95, a quick ratio of 14.95 and a debt-to-equity ratio of 0.54.
Celcuity (NASDAQ:CELC – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. During the same period last year, the company earned ($0.66) earnings per share. On average, equities research analysts forecast that Celcuity will post -2.54 EPS for the current fiscal year.
Analyst Ratings Changes
Read Our Latest Stock Report on Celcuity
Hedge Funds Weigh In On Celcuity
Several large investors have recently made changes to their positions in CELC. Commodore Capital LP raised its position in Celcuity by 3.6% in the fourth quarter. Commodore Capital LP now owns 1,754,704 shares of the company’s stock valued at $25,566,000 after purchasing an additional 60,563 shares during the period. Baker BROS. Advisors LP raised its holdings in shares of Celcuity by 189.9% in the 1st quarter. Baker BROS. Advisors LP now owns 1,552,478 shares of the company’s stock valued at $33,534,000 after buying an additional 1,017,000 shares during the period. Perceptive Advisors LLC acquired a new position in Celcuity during the 4th quarter worth about $21,583,000. Samlyn Capital LLC boosted its holdings in Celcuity by 92.4% during the 2nd quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock valued at $21,735,000 after acquiring an additional 637,190 shares during the period. Finally, Vanguard Group Inc. grew its position in Celcuity by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 828,597 shares of the company’s stock valued at $17,898,000 after acquiring an additional 7,821 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.
Celcuity Company Profile
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
See Also
- Five stocks we like better than Celcuity
- Best Stocks Under $5.00
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- What Investors Need to Know About Upcoming IPOs
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Canada Bond Market Holiday: How to Invest and Trade
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.